Erivedge
(Vismodegib)ApprovedSmall molecule
RocheVismodegib is used to treat certain types of skin cancer called basal cell carcinoma, particularly in patients with advanced disease or those who cannot undergo surgery or radiation therapy.[2] Erivedge is currently approved and in use across 17 indications[4].[1]
Erivedge is one of 309 small molecule programs targeting Nevoid Basal Cell Carcinoma Syndrome. It is currently in Approved.
17
Indications
75
Total Trials
15
Active Trials
308
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Erivedge
RocheApproved
Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Basal Cell Carcinoma21 trials
Show 18 more trials
Vismodegib for Treatment of Basal Cell Carcinoma
Completed·—·Phase 2·NCT01543581·3 enrolled
Medulloblastoma5 trials
Pancreatic Cancer4 trials
Trial3 trials
Breast Cancer2 trials
37 more indications
Idiopathic Pulmonary Fibrosis2 trials
Cancer2 trials
Advanced Lymphoma2 trials
Clinical Trial1 trial
Chronic Lymphocytic Leukemia1 trial
Glioma1 trial
Primary Peritoneal Cancer1 trial
Myelodysplastic Syndrome1 trial
Multiple Myeloma1 trial
Prostate Cancer1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Metastatic1 trial
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02115828·9 enrolled
Glioblastoma Multiforme1 trial
Myelofibrosis1 trial
Chronic Graft Versus Host Disease1 trial
Metastatic Sarcoma1 trial
Metastatic Colorectal Cancer1 trial
Ovarian Cancer1 trial
Gastric Adenocarcinoma1 trial
Basal Cell Nevus Syndrome1 trial
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Withdrawn·—·Phase 2·NCT03767439
Hepatocellular Carcinoma1 trial
Skin Cancer1 trial
Interaction1 trial
Advanced Solid Tumors1 trial
Gastroesophageal Junction Cancer1 trial
Keratocystic odontogenic tumor1 trial
Intracranial Meningioma1 trial
Metastatic Lung Non-Small Cell Carcinoma1 trial
Adult Solid Neoplasm1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 30, 2012
ERIVEDGE
NDA NDA203388
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Erivedge drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Vismodegib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]